← Leaderboards
Joel Steven Ross
Rh Nanopharmacueticals L.L.C.
$1,384,976
Attributed
$1,384,976
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1000K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$1,384,976 · 1
By mechanism
R44$1,384,976 · 1
Top collaborators
No co-investigators on record.
Most similar at Rh Nanopharmacueticals L.L.C.
Same institution · by research overlap
- Izhar Hasan$701,392
Others in their field
Other Emerging Leaders on “Acute Pain”
- Abraham Aizer Brody · New York University School Of Medicine$18,899,006
- Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
- Bryan L McLaughlin · Micro-Leads, Inc.$9,612,607
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Jeffrey Reich · Sparian Biosciences, Inc.$8,261,211
- Joseph A Janicki · Lurie Children'S Hospital Of Chicago$5,541,590
Research focus
Acute PainAddictionAdverse EffectsAdverse EventAffectAmericanAnalgesicsAnimal ModelAnimal PainAnimalsAreaArea Under CurveBaseBindingBiodistributionBrain TissueCanis FamiliarisCardiovascular SystemCarrageenanChemistryChronic PainClinical ResearchCombatAcute
Grant awards (3)
Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management$999,994
R44 · FY2021 · NS · contact PI
Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management$85,000
R44 · FY2020 · NS · contact PI
Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management$299,982
R44 · FY2019 · NS · contact PI